Continuing to build its dermatology portfolio, LEO Pharma has entered into a global licensing agreement with JW Pharmaceutical gaining exclusive rights to develop and commercialise an atopic dermatitis drug candidate, JW1601. The global agreement, which excludes the Korean market, is potentially worth up to US$402 M and comes after LEO’s acquisition of Bayer’s prescription dermatology unit in July 2018 to enhance its global presence and its divestment of 10 established products.